In 2015, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, the National Women’s Health Network launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like dangerously low blood pressure, dizziness, and even sudden loss of consciousness.

Photos taken at the 8th Annual Barbara Seaman Awards for Activism in Women’s Health event.

The NWHN has issued a report card, Addyi One Year Later: What’s the Score?” The report grades the manufacturer, Valeant Pharmaceuticals, upon careful review of their performance. After one year, we’ve seen a lot of broken promises, studies that were never conducted, and faulty training practices.

Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.

Resources

Addyi Timeline Factsheet
Addyi Timeline Fatchseet

Want to know how this bogus drug got on the market?

Addyi Factsheet Trails
Clinical Trials Fatchseet

Get more information about the faulty clinical trials on Addyi.

Additional Resources:

  • Addyi Consumer Alert: An emergency consumer alert was issued to warn women of the dangers of Addyi. Learn why women should pass on the pink pill.
  • Top 10 Things to Know: Whether you are thinking of speaking with your doctor about Addyi or interested in learning more about this new drug. Read List
  • Report Reactions: Adverse reactions to Addyi should be reported to the Federal Drug Administration at FDA.gov/medwatch or call 1-800-FDA-1088.

Highlighted Content Related To Sex Drugs For Women:

Sex Drugs for Women: Myths and Marketing Messages

Comments Off on Sex Drugs for Women: Myths and Marketing Messages

Vyleesi: Another Attempt to Profit from Women’s Health 

Comments Off on Vyleesi: Another Attempt to Profit from Women’s Health 

The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

Comments Off on The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

FDA to Consider Controversial Female Sexual Dysfunction Drug for the Third Time

Comments Off on FDA to Consider Controversial Female Sexual Dysfunction Drug for the Third Time

The National Women’s Health Network Expresses Profound Disappointment With FDA’s Decision to Approve Controversial Sex Drug.

Comments Off on The National Women’s Health Network Expresses Profound Disappointment With FDA’s Decision to Approve Controversial Sex Drug.

Flibanserin Approved… Women’s Health and Safety Ignored!

Comments Off on Flibanserin Approved… Women’s Health and Safety Ignored!